Robert W. Baird Boosts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $62.00
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price upped by Robert W. Baird from $52.00 to $62.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the stock. CRNX has been the topic of several other research reports. Oppenheimer boosted their price target on […]
More Stories
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ) Sees Significant Increase in Short Interest
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ – Get Free Report) was the recipient of a significant increase in short...
Analysts’ Recent Ratings Updates for Arch Resources (ARCH)
Several analysts have recently updated their ratings and price targets for Arch Resources (NYSE: ARCH): 11/19/2024 – Arch Resources is...
Verity & Verity LLC Raises Position in American Express (NYSE:AXP)
Verity & Verity LLC increased its holdings in shares of American Express (NYSE:AXP) by 2.5% during the 3rd quarter, according...
Caldwell Investment Management Ltd. Makes New $995,000 Investment in Oracle Co. (NYSE:ORCL)
Caldwell Investment Management Ltd. acquired a new stake in Oracle Co. (NYSE:ORCL – Free Report) in the 3rd quarter, according...
Fortis Advisors LLC Increases Position in iShares Core Dividend Growth ETF (NYSEARCA:DGRO)
Fortis Advisors LLC boosted its holdings in iShares Core Dividend Growth ETF (NYSEARCA:DGRO – Free Report) by 96.7% in the...
The Coca-Cola Company (NYSE:KO) Shares Sold by Belmont Capital LLC
Belmont Capital LLC lessened its holdings in shares of The Coca-Cola Company (NYSE:KO – Free Report) by 91.3% in the...